Evidence map›Paper›PMID 31428176›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2019

Mayra Alejandra Santillán-Urquiza, Maribel Herrera-Ruiz, Alejandro Zamilpa, Enrique Jiménez-Ferrer, Rubén Román-Ramos, Elian Yuritzi Alegría-Herrera, Jaime Tortoriello

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Herniarin, Dimethylfraxetin and Extracts fromPlants (Basel, Switzerland) · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mayra Alejandra Santillán-UrquizaCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.
Maribel Herrera-RuizCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.ORCID https://orcid.org/0000-0001-9056-3568
Alejandro ZamilpaCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.ORCID https://orcid.org/0000-0002-2233-5958
Enrique Jiménez-FerrerCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.ORCID https://orcid.org/0000-0002-0783-8274
Rubén Román-RamosLaboratorio de Farmacología, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana (UAM), Mexico City, Mexico.
Elian Yuritzi Alegría-HerreraCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.
Jaime TortorielloCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790 Xochitepec, Morelos, Mexico.ORCID https://orcid.org/0000-0002-1597-7645
Mexican Social Security Institute · MXUniversidad Autónoma Metropolitana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodOn the first day, ICR male mice were given GgMeOH, GRF, or one of the galphimines. On day two, animals were treated with APO, and on day 3, they were subjected to behavioral tests. In a second test, MK-801 was administered daily for 28 days. In this case, animals were treated daily with

resultsThe increased number of stereotyped behaviors and grooming behaviors induced with APO were counteracted by all of the experimental treatments. MK-801 induced an increase in immobility time, which was blocked with G-B; GRF counteracted the decreased social interaction, and GgMeOH and GRF prevented the memory loss induced by MK-801.

conclusion

Identifiers

PMID31428176
PMCPMC6679897
OpenAlexW2964226833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.